secwatch.observer — SEC 8-K summary
======================================

Issuer:     AETHLON MEDICAL INC (AEMD)
CIK:        0000882291
Form:       8-K
Filed at:   2023-08-10T23:59:59+00:00
Accession:  0001683168-23-005510
Event type: earnings
Sentiment:  negative
Materiality: 0.50
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Aethlon Medical Q1 FY2024 net loss $3.3M, cash $12.9M; Hemopurifier progress
----------------------------------------------------------------------------

- Net loss widened to $3.3M for quarter ended June 30, 2023 from $2.9M a year ago; operating expenses rose 17.3% to $3.4M.
- Cash balance $12.9M at quarter end; raised $1.1M net proceeds via at-the-market equity facility with H.C. Wainwright.
- COVID-19 ICU trial in India remains open; second site Maulana Azad Medical College received Ethics Board approval.
- Entered research collaboration with 34 Lives to test Hemopurifier in machine perfusion of recovered kidneys.
- Oncology feasibility trial in Australia with NAMSA for solid tumors failing anti-PD-1 therapy is ongoing.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/882291/000168316823005510/0001683168-23-005510-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/882291/000168316823005510/aethlon_8k.htm
  HTML page:      https://secwatch.observer/filing/0001683168-23-005510

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer